Q-omics provides the consensus-scored CRYZP1 profile across patient tissues and cancer cell-line models. CRYZP1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CRYZP1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CRYZP1 RNA expression shows 19,865 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where CRYZP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYZP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYZP1 survival associations across molecular data types. CRYZP1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYZP1 RNA expression–survival associations across cancer types. High CRYZP1 expression shows unfavorable associations in LGG, KICH, CESC and KIRC, but favorable associations in LAML and UCS. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CRYZP1 RNA expression.
This table summarizes CRYZP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CRYZP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYZP1 shows lower tumor expression in THCA and higher tumor expression in HNSC, CHOL, LIHC, KIRC and READ. The HNSC box plot shows higher CRYZP1 RNA expression in tumor versus normal tissue (log2 FC = +0.171, t-test p < 0.001).
This table shows molecular features associated with CRYZP1 in patient tissues and cancer cell lines. In patient samples, CRYZP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
